GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Aug 20, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

11 papers

Active filtersClassification:Core

Showing 1-11 of total 11 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2025OpenAlexDirectly related117 citations

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

Sean Wharton; Louis J. Aronne; Adam Stefański; Nasreen Alfaris; Andreea Ciudin; Koutaro Yokote; Bruno Halpern; Alpana P. Shukla; Chunmei Zhou; Lisa Macpherson; Sheryl Allen; Nadia N. Ahmad; Suzanne Klise

Sep 16, 2025New England Journal of Medicine

2025OpenAlexDirectly related63 citations

The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy

Nadia J Abbass; Raya Nahlawi; Jacqueline K. Shaia; Kevin Allan; David C. Kaelber; Katherine E. Talcott; Rishi P. Singh

Feb 25, 2025American Journal of Ophthalmology

2023OpenAlexDirectly related117 citations

The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)

Roger S. McIntyre; Rodrigo B. Mansur; Joshua D. Rosenblat; Angela T.H. Kwan

Dec 13, 2023Expert Opinion on Drug Safety

2023OpenAlexDirectly related237 citations

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

Jingyue Wang; Quanwei Wang; Xinyu Yang; Wei Yang; Dong-Rui Li; Jingyu Jin; Hui-Cong Zhang; Xianfeng Zhang

Feb 1, 2023Frontiers in Endocrinology

2021OpenAlexDirectly related435 citations

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Xin Zhao; Minghe Wang; Zhitong Wen; Zhihong Lu; Lijuan Cui; Chao Fu; Huan Xue; Yunfeng Liu; Yi Zhang

Aug 23, 2021Frontiers in Endocrinology

2021OpenAlexDirectly related1,961 citations

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Juan P. Frías; Melanie J. Davies; Julio Rosenstock; Federico C. Pérez Manghi; Laura Fernández Landó; Brandon K. Bergman; Bing Liu; Xuewei Cui; Katelyn Brown

Jun 25, 2021New England Journal of Medicine

2020OpenAlexDirectly related1,951 citations

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome; Kristine Buchholtz; Kenneth Cusi; Martin Linder; Takeshi Okanoue; Vlad Ratziu; Arun J. Sanyal; Anne‐Sophie Sejling; Stephen A. Harrison

Nov 13, 2020New England Journal of Medicine

2020OpenAlexDirectly related1,561 citations

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

Michael A. Nauck; Daniel R. Quast; Jakob Wefers; Juris J. Meier

Oct 14, 2020Molecular Metabolism

2019OpenAlexDirectly related930 citations

The Discovery and Development of Liraglutide and Semaglutide

Lotte Bjerre Knudsen; Jesper Lau

Apr 12, 2019Frontiers in Endocrinology

2018OpenAlexDirectly related850 citations

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Tamer Coşkun; Kyle W. Sloop; Corina Loghin; Jorge Alsina‐Fernandez; Shweta Urva; Krister Bokvist; Xuewei Cui; Daniel A. Briere; Over Cabrera; William C. Roell; Uma Kuchibhotla; Julie S. Moyers; Charles Benson; Ruth E. Gimeno; David A. D’Alessio; Axel Haupt

Oct 3, 2018Molecular Metabolism

2017OpenAlexDirectly related585 citations

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Michael A. Nauck; Juris J. Meier; Matthew A. Cavender; Mirna Abd El Aziz; Daniel J. Drucker

Aug 28, 2017Circulation